NEAUTUS (02206.HK): IPO closes with 1,115x margin orders, listing 11 Nov

NewTimeSpace News: On 6 November 2026, Sichuan Neautus Traditional Chinese Medicine Co., Ltd. (02206.HK) closed its IPO subscription on 6 November. The company planned to offer 6,517,300 H shares globally at HK$40.20 to HK$50.55 per share, in board lots of 50 shares with an entry fee of HK$2,552.99. The Hong Kong public offer accounted for 651,750 shares (10%) and the international placing 5,865,550 shares (90%), with results expected on 10 November and listing on 11 November.

According to broker margin financing data, as of 13:45 on 6 November, total margin subscription capital for the Hong Kong public offer reached about HK$36.739 billion, equivalent to about 1,115.14 times the public offer fund-raising amount of HK$32.95 million. Based on a 10% offer ratio, the total issued share capital after the offer will be about 65,172,700 shares; at the offer price range, gross proceeds are about HK$262 million to HK$329 million, with listing expenses of about HK$66.10 million and net proceeds of about HK$230 million.

Of the net proceeds, about 33.4% (about HK$76.7 million) will be used to expand TCM decoction-piece production capacity and upgrade digital smart manufacturing systems, about 29.0% (about HK$66.6 million) for sales and marketing, about 11.4% (about HK$26.2 million) for consumer-facing business spending, about 10.2% (about HK$23.4 million) to build overseas sales channels in Vietnam and Malaysia, about 6.0% (about HK$13.8 million) for strategic investments and potential acquisitions, and the remaining about 10.0% (about HK$23.0 million) for working capital and other general corporate purposes.